Weekly Digest - June 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - June 2024
3 June 2024: Debiopharm and Genome & Company strike deal for groundbreaking oncology Antibody Drug Conjugate portfolio
- Debiopharm and Genome & Company have signed an exclusive licensing agreement for the development of potential first-in-class antibody-drug conjugates
- The agreement grants Debiopharm global rights to combine Genome & Company’s antibodies with Debiopharm’s Multilink™ linker technology for creating innovative therapeutic agents targeting hard-to-treat cancers
- Debiopharm’s Multilink™ technology offers improved linker stability and drug release, enhancing treatment specificity and effectiveness
- With the growing interest in ADC development, linker design has become crucial, as few linkers provide the stability needed for specific and effective drug release
